Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
NCT07760038 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2026-08-12
Summary
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed. The study will also look at whether phycocyanin is safe to take.The main questions are:
Does phycocyanin reduce liver injury after surgery? Does it help the liver grow back and recover? What side effects or medical problems happen while taking it?
Researchers will compare phycocyanin with a placebo, which looks similar but does not contain phycocyanin. About 30 people will take part. Each person will be randomly placed into one of the two groups, and neither the participants nor the researchers will know which treatment each person receives during the study.
Participants will:
Take 1.5 grams of phycocyanin or placebo every day for 3 weeks before surgery and 3 weeks after surgery Receive the usual care for liver surgery Give blood and stool samples before and after treatment Allow researchers to study a small piece of liver tissue removed during surgery Return for follow-up for up to 90 days after surgery
The samples will be used to check liver function, inflammation, gut bacteria, and changes linked to liver healing. Possible side effects include an allergic reaction or stomach discomfort. The study has been approved by an ethics committee.
Conditions
- Intrahepatic Cholangiocarcinoma (Icc)
- Liver Injury
Interventions
- DIETARY_SUPPLEMENT
-
Phycocyanin
Participants will take 1.5 grams of phycocyanin by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. Phycocyanin is a natural protein from spirulina.
- DIETARY_SUPPLEMENT
-
Maltodextrin
Participants will take 1.5 grams of maltodextrin placebo by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. The placebo does not contain phycocyanin.
Sponsors & Collaborators
-
Second Affiliated Hospital, Zhejiang University, School of Medicine
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-01
- Primary Completion
- 2029-05-30
- Completion
- 2029-05-30
Countries
- China
Study Locations
More Related Trials
-
Study on Safety, Tolerance and Metabolic Effects of a Nutritional Supplement, Given as a Drink Before Gallbladder Surgery
NCT00662376 ·Status: COMPLETED ·Phase: NA
-
Impact of Perioperative Allogeneic Red Blood Cell Transfusion on Postoperative Myocardial Injury After Liver Resection
NCT07125612 ·Status: COMPLETED
-
Effects of N-acetylcysteine on Pulmonary Function in High-risk Patients Undergoing Off-pump Coronary Bypass Surgery
NCT01021163 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Remote Ischemic Preconditioning and Postconditioning on Lung Injury During Cardiopulmonary Bypass
NCT01144585 ·Status: COMPLETED ·Phase: NA
-
The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound.
NCT06398028 ·Status: RECRUITING ·Phase: PHASE4
-
Comparison of 6% Hydroxyethyl Starch 130/0.4 With 5% Albumin as Priming Solution for Cardiopulmonary Bypass
NCT00978588 ·Status: COMPLETED ·Phase: NA
-
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery
NCT02191839 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Light Therapy in Cardiopulmonary Bypass Surgery
NCT02928887 ·Status: WITHDRAWN ·Phase: NA
-
Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass
NCT05610475 ·Status: COMPLETED ·Phase: NA
-
Clinical and Chemical Outcomes Following Cardiac Surgery: The Post-Operative Effects of MUF
NCT01864395 ·Status: UNKNOWN ·Phase: NA
-
Inflammatory Genetic Polymorphism and Acute Lung Injury After Cardiac Surgery
NCT00826072 ·Status: COMPLETED
-
Effects of Hypoxic-hyperoxic Preconditioning in Cardio-surgical Patients
NCT05354648 ·Status: COMPLETED ·Phase: NA
-
Management of Bleeding Following Cardiopulmonary Bypass
NCT00672516 ·Status: COMPLETED
-
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
NCT02068716 ·Status: COMPLETED
-
Immunonutrition in Cardiac Surgery
NCT00247793 ·Status: COMPLETED ·Phase: NA
-
The Protection of ACD III on Erythrocytes in Intraoperative Blood Salvage During Cardiopulmonary Bypass
NCT05267145 ·Status: UNKNOWN ·Phase: NA
-
The Perioperative Risks of Adverse Events After Cardiac Surgery: a Retrospective Study
NCT04476134 ·Status: UNKNOWN
-
Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery
NCT04244981 ·Status: TERMINATED ·Phase: PHASE4
-
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
NCT02073760 ·Status: COMPLETED
-
A Comparison Between 5% Albumin and 6% Hydroxyethyl Starch 130/0.4 in Priming Solution for Cardiopulmonary Bypass and Post-bypass Maintenance Fluid in High-risk Patients
NCT01644084 ·Status: COMPLETED ·Phase: NA
-
Cardiac Surgery: In Vivo Titration of Protamine
NCT00684450 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
NCT07094087 ·Status: RECRUITING ·Phase: PHASE3
-
SGB Reduces the Incidence and Severity of CSA-AKI
NCT05652179 ·Status: COMPLETED ·Phase: NA
-
Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass
NCT01478126 ·Status: COMPLETED ·Phase: PHASE3
-
Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass
NCT03500783 ·Status: COMPLETED ·Phase: PHASE1/PHASE2